Deucrictibant XR Reduces Hereditary Angioedema Attacks
Pharvaris reported that once-daily oral deucrictibant XR reduced mean monthly hereditary-angioedema attack rates by 83% versus placebo in the pivotal Phase III CHAPTER-3 study. The 85-participant trial met its primary endpoint and all multiplicity-controlled…
